PT-141: Desire, Timing and Vyleesi Doses
PT-141 · bremelanotide · Vyleesi
People seek PT-141 to improve sexual desire. Its approved version, Vyleesi, is an as-needed treatment for distressing low desire in premenopausal women. Nausea and temporary blood-pressure increases are the main practical trade-offs.
Desire, arousal and erections are different questions. Vyleesi's approval does not cover men, postmenopausal women or general sexual-performance enhancement.
Vyleesi is used as needed
Approved autoinjector · under the skin
1.75 mg Prescribed dose
45+ min Before anticipated activity
This is the label's timing instruction. It does not promise when a benefit will start or how long it will last.
- 24 hours
- No more than one dose
- 8 per month
- More doses not recommended
Vyleesi dose and timing at a glance
The visual shows approved-product instructions, not a general peptide regimen. Vyleesi treats acquired, generalized HSDD: low desire that developed after a period without the problem, occurs across situations and causes distress. It is not intended for desire problems caused by an illness, another medicine or relationship difficulties. Vyleesi label.
What benefit did the trials measure?
Improved
Desire and related distress
Average questionnaire scores improved more than with placebo over 24 weeks.
No clear increase
Number of satisfying sexual events
This separate outcome did not improve significantly versus placebo.
The two RECONNECT trials studied premenopausal women with HSDD, using 1.75 mg subcutaneous bremelanotide as needed. Improvement was measured across 24 weeks; it does not promise a response after every injection. Original trials.
How bremelanotide works
Bremelanotide acts on melanocortin receptors, which are involved in several signaling pathways. It is not hormone replacement, and the precise way it improves HSDD remains unknown. A simple “libido switch” explanation overstates what is established.
How fast does PT-141 work, and how long does it last?
There is no dependable fixed duration of benefit in the label. Its 45-minute instruction describes when to give Vyleesi before anticipated activity, rather than a guaranteed onset. Online reports of a much longer or shorter experience cannot establish an exact window.
The label reports a plasma peak around one hour and a mean half-life around 2.7 hours. Those measurements describe drug exposure, not a countdown for desire or erections. See the PT-141 curve and model details.
Side effects and risks
- Nausea: about 40% of Vyleesi-treated participants reported it in the pooled trials. This is a share of participants, not a 40% chance after each dose. Flushing and headache also occurred. RECONNECT.
- Blood pressure: Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease.
- Other medicines and skin changes: delayed stomach emptying can affect oral medicines, notably naltrexone. Focal darkening of skin or gums can persist.
Review medicines, cardiovascular history and pregnancy plans with the prescriber. Persistent or severe nausea needs advice. Product precautions.
Bremelanotide benefits for men
Men ask about desire and erection effects, but Vyleesi is not approved for men. Early studies did investigate erectile responses: one crossover study enrolled 19 men with erectile dysfunction and tested an intranasal formulation with sildenafil. That different route and combination cannot establish an injection regimen for men or equivalence of online nasal sprays. Original study.
PT-141, Vyleesi, and the intranasal question
| Name on the product | What to check |
|---|---|
| Vyleesi | Approved autoinjector, labeled indication and prescribing information |
| PT-141 research vial | Identity, formulation and human-use status are not established by the name |
| Intranasal PT-141 | A different route; injection exposure numbers and instructions do not transfer |
FAQ
Is it the same as Viagra or Cialis? No. Those medicines and bremelanotide act differently. A desire treatment and an erectile-dysfunction treatment are not interchangeable, and early combination research is not a self-directed stacking plan.
Why can pigmentation change? Melanocortin signaling includes pigment pathways. The label warns that focal darkening may persist.
Sources
Checked October 11, 2026.
- Vyleesi prescribing information: sections 1–2, 4–7, 12 and 14 for indication, on-demand dosing, duration uncertainty, precautions and trial outcomes.
- RECONNECT phase 3 publication and full text: two 24-week, randomized, placebo-controlled trials in premenopausal women with HSDD; desire, distress and nausea context.
- Intranasal PT-141/sildenafil crossover study: early male research in 19 participants; route and combination differ from the approved product.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.